These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7584910)

  • 1. Effects of Ca-antagonists on oxidative susceptibility of low density lipoprotein (LDL).
    Yoshida H; Ayaori M; Suzukawa M; Hosoai H; Nishiwaki M; Ishikawa T; Nakamura H
    Hypertens Res; 1995 Mar; 18(1):47-53. PubMed ID: 7584910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein.
    Rojstaczer N; Triggle DJ
    Biochem Pharmacol; 1996 Jan; 51(2):141-50. PubMed ID: 8615882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia.
    Napoli C; Postiglione A; Triggiani M; Corso G; Palumbo G; Carbone V; Ruocco A; Ambrosio G; Montefusco S; Malorni A; Condorelli M; Chiariello M
    Atherosclerosis; 1995 Dec; 118(2):259-73. PubMed ID: 8770320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced susceptibility to oxidation of low-density lipoprotein in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome).
    Calò L; Sartore G; Bassi A; Basso C; Bertocco S; Marin R; Zambon S; Cantaro S; D'Angelo A; Davis PA; Manzato E; Crepaldi G
    J Hypertens; 1998 Jul; 16(7):1001-8. PubMed ID: 9794741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over over study.
    Rachmani R; Lidar M; Brosh D; Levi Z; Ravid M
    Diabetes Res Clin Pract; 2000 May; 48(2):139-45. PubMed ID: 10802151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidation.
    Kritz H; Oguogho A; Aghajanian AA; Sinzinger H
    Prostaglandins Leukot Essent Fatty Acids; 1999 Sep; 61(3):183-8. PubMed ID: 10582658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma thiols inhibit hemin-dependent oxidation of human low-density lipoprotein.
    Lynch SM; Campione AL; Moore MK
    Biochim Biophys Acta; 2000 May; 1485(1):11-22. PubMed ID: 10802245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation.
    Sobal G; Menzel EJ; Sinzinger H
    Biochem Pharmacol; 2001 Feb; 61(3):373-9. PubMed ID: 11172743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol.
    Lupo E; Locher R; Weisser B; Vetter W
    Biochem Biophys Res Commun; 1994 Sep; 203(3):1803-8. PubMed ID: 7945331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis.
    Inouye M; Mio T; Sumino K
    Eur J Clin Pharmacol; 2000 Apr; 56(1):35-41. PubMed ID: 10853875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats.
    Napoli C; Salomone S; Godfraind T; Palinski W; Capuzzi DM; Palumbo G; D'Armiento FP; Donzelli R; de Nigris F; Capizzi RL; Mancini M; Gonnella JS; Bianchi A
    Stroke; 1999 Sep; 30(9):1907-15. PubMed ID: 10471444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease.
    Chiu HC; Jeng JR; Shieh SM
    Biochim Biophys Acta; 1994 Jan; 1225(2):200-8. PubMed ID: 8280789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals.
    Napoli C; Chiariello M; Palumbo G; Ambrosio G
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):417-24. PubMed ID: 8924055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein composition and oxidability in atherosclerotic cardiovascular disease.
    Schreier LE; Sanguinetti S; Mosso H; Lopez GI; Siri L; Wikinski RL
    Clin Biochem; 1996 Oct; 29(5):479-87. PubMed ID: 8884071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin inhibits oxidative modification of low-density lipoprotein particles in normolipidemic post-menopausal women.
    Wakatsuki A; Okatani Y; Ikenoue N; Izumiya C; Kaneda C
    J Pineal Res; 2000 Apr; 28(3):136-42. PubMed ID: 10739299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative modification of lipoproteins in hypertriglyceridemic patients and hypercholesterolemic rabbits in vivo.
    Liu BW; Jiang Y; Fu MD; Liu Y; Fan P
    Mol Cell Biochem; 2000 Apr; 207(1-2):131-5. PubMed ID: 10888238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3.
    Hansel B; Girerd X; Bonnefont-Rousselot D; Bittar R; Chantepie S; Orsoni A; Bruckert E; Chapman MJ; Kontush A
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):317-25. PubMed ID: 21699274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactions.
    Phillips JE; Preston Mason R
    Atherosclerosis; 2003 Jun; 168(2):239-44. PubMed ID: 12801606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of LDL oxidation by a new estradiol receptor modulator compound LY-139478, comparative effect with other steroids.
    Rattan AK; Arad Y
    Atherosclerosis; 1998 Feb; 136(2):305-14. PubMed ID: 9543102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.